Shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) rose 5.2% during trading on Monday . The company traded as high as $4.65 and last traded at $4.64, with a volume of 444,034 shares. The stock had previously closed at $4.41.

SGMO has been the subject of a number of research analyst reports. Janney Montgomery Scott lowered Sangamo BioSciences from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $15.00 to $8.00 in a research note on Thursday, August 4th. Jefferies Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Sangamo BioSciences in a research note on Thursday, June 9th. Cowen and Company reaffirmed a “buy” rating on shares of Sangamo BioSciences in a research note on Wednesday, August 10th. Wells Fargo & Co. initiated coverage on Sangamo BioSciences in a research note on Tuesday, May 3rd. They issued a “buy” rating for the company. Finally, Zacks Investment Research lowered Sangamo BioSciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $15.58.

The company’s 50-day moving average is $5.64 and its 200 day moving average is $5.97. The stock’s market capitalization is $317.78 million.

Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.14. During the same quarter last year, the firm earned ($0.17) earnings per share. The firm earned $3.70 million during the quarter, compared to analyst estimates of $5.38 million. The company’s quarterly revenue was down 56.0% on a year-over-year basis. On average, equities research analysts forecast that Sangamo BioSciences Inc. will post ($1.11) EPS for the current fiscal year.

An institutional investor recently raised its position in Sangamo BioSciences stock. Royce & Associates LLC increased its position in Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned approximately 0.45% of Sangamo BioSciences worth $2,849,000 as of its most recent filing with the SEC.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.